Silo Pharma Inc. (NASDAQ:SILO) shares surged 47.55% in after-hours trading Monday to $0.52 following a key intellectual property update tied to its PTSD treatment pipeline.
Patent Development
On Monday, the company said the European Patent Office issued a Rule 71(3) communication indicating its intent to grant a patent covering a novel preventative therapy targeting the serotonin 4 (5-HT4) receptor pathway.
The patent, licensed from Columbia University, focuses on preventing stress-induced fear and depressive-like behavior using 5-HT4 receptor agonists, an approach aimed at addressing stress resilience rather than treating symptoms after onset.
The allowed claims are expected to cover major European markets, with the company evaluating additional protections, including Unitary Patent coverage and national validations.
Full story available on Benzinga.com
This post was originally published here